Low-dose continuous chemotherapy for metastatic melanoma: A phase II trial

Melanoma Research

Volumn 13, Issue 2, 2003, Pages 197-199

  Nystrom, Maria L ^a   Steele, Jeremy P C ^a   Shamash, Jonathan ^a   Neville, Frances ^a   Oliver, R Timothy D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Bleomycin; Low dose chemotherapy; Melanoma

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; FOLINIC ACID; LOMUSTINE; METHOTREXATE; TAMOXIFEN; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRONCHIOLITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; INFECTION; LOW DRUG DOSE; LUNG DISEASE; MALAISE; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORGANIZING PNEUMONIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SURVIVAL RATE; SYMPTOMATOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LOMUSTINE; MALE; MELANOMA; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0037903784     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200304000-00014     Document Type: Article

References (14)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14:7-17.
2. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999; 17:2752-2761.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
4. Legha SS. Current therapy for malignant melanoma. Semin Oncol 1989; 16(1 suppl 1):34-44.
5. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicentre trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
6. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13:73-80.
7. Shamash J, Walewski J, Apostolidis J, Wilson AM, Foran JM, Gupta RK, et al. Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. Ann Oncol 2000; 11:857-860.
8. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, et al. Randomized, double- blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2083-2090.
9. Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17:1884-1890.
10. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996; 156:1353-1357.
11. Bernd A, Altmeyer P, Schafer G, Marsch WC, Holzmann H. Bleomycin enhances the tyrosinase activity of human malignant melanoma cells in culture. Pharmacol Res Commun 1986; 18:1075-1091.
12. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumour growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4:1331-1336.
13. Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99:823-833.
14. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13:910-913.